AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Monitoring Agency Report 8 Oct - ICRA monitoring report for quarter ended September 30, 2026 shows no material deviation in IPO proceeds use.
Source: Bse
Laxmi Dental Limited (LAXMIDENTL)
Small CapPharma stocks · Small cap · NSE
Laxmi Dental Limited operates in Dental Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result11 Aug, 06:39 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
51Neutralfull bear SMA stack · SMA20 -2.6% / mo · MACD − · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 18
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
LAXMIDENTLD candles · FIT view-7.5%Latest close ₹177.96 on 2026-10-21
Bar
-1.5%
RSI
30
MACD hist
-1.31
52W pos
12%
2026-10-21O ₹180.66H ₹184.96L ₹177.00C ₹177.96Vol 57,366 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
LAXMIDENTLNifty PharmaNifty 500
- LAXMIDENTL
- -20.9%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -14.4 pp
Chart stats
21 Oct 2026- From 52W high
- -48.4%
- 52W range position
- 12%
- ATR (14)
- 3.8%
- Volume vs 20D
- 0.83x
- Avg traded value
- ₹1.3 Cr
- 20D price channel
- ₹177 - ₹201.6
₹344.8
₹155.9 - ₹344.8
₹6.8
Latest completed session
20-session average
29.6% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE56
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good70
Revenue +13.6% · PAT +25.0% YoY
Technical
Neutral51
Price trend and sector-relative-strength timing.
Valuation
Legacy model+29.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence70
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 70/100Rev +14% YoY · PAT +25% YoY · margin expansion · operating leverage
Filed 11 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹75 Cr | +13.6% | +1.4% |
| EBITDA | ₹14 Cr | +16.7% | +0.0% |
| Operating margin | 19.0% | +100 bps | +100 bps |
| PAT | ₹10 Cr | +25.0% | +0.0% |
| PAT margin | 13.3% | +121 bps | -18 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 30.20
- P/B
- 4.31
- EV/EBITDA
- 16.86
- Market Cap
- 1049.00Cr
Profitability
- ROE
- 14.80%
- ROCE
- 15.00%
- ROA
- 10.44%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 25.00%
- EPS 5Y
- 103.00%
- Revenue 3Y
- 20.00%
- EPS 3Y
- 124.00%
Balance Sheet
- Debt/Equity
- 0.05
- Interest Coverage
- 46.00×
- Altman Z
- 8.87
- Book Value
- 44.30
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- -5.00 Cr
- EPS TTM
- 5.61
Shareholding
- Promoter Hold
- 41.80%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 19%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 75.0+1.4% vs prev
Net Profit
₹ CrLatest: 10.0+0.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 30.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~2.6% over last month) — short-term momentum negative.
- RSI(14) at 30 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 48% off 52W high · 14% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
20
RS percentile
Stage 1 Base / Transition
1M return
-8.7%
3M return
-20.9%
6M return
-8.3%
1Y return
-43.2%
RS 1D
0
RS 20D
-1
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 13.5% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +0.7% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 58.08-1.19%
RS vs Nifty 50058
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 56 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
FAIR_VALUE
Fundamental score breakdown
U band · FAIR VALUEValuation7/30
Growth24/25
Quality9/20
Balance Sheet9/15
Cash Flow3/10
Piotroski
6/9 (+3)
Penalties
1
Raw sum
56
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
56/100 · legacy band FAIR VALUE
Positive drivers
- Fair-value margin of safety is positive at 29.5%.
- Growth contributes 24/25 to the score.
- Balance sheet contributes 9/15 to the score.
Main drags
- Valuation is weaker at 7/30; verify the latest quarterly trend.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
- Quality is weaker at 9/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
30.2
PB
4.3
EV/EBITDA
16.9
ROE
14.8%
ROCE
15.0%
FCF Yield
—
Debt/Equity
0.1
MoS
+29.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
56
Previous: 56
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+29.5%
Previous: +28.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
54
54
54
54
54
54
54
56
56
56
56
56
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹74.78
-138.0% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹252.45
+29.5% MoS
PEG
0.27
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
DENTALKART
SME
Vasa Denticity Ltd.
Healthcare Services
match 156
14
69.4
4.5%
-1604%
OVERVALUED
LINCOLN
Small
Lincoln Pharmaceuticals Limited
Healthcare Services
match 139
57
11.8
12.3%
+32%
FAIR VALUE
KILITCH
Small
Kilitch Drugs (India) Limited
Healthcare Services
match 137
50
27.5
10.6%
+43%
FAIR VALUE
GAUDIUMIVF
Small
Gaudium IVF and Women Health Limited
Healthcare Services
match 137
56
32.4
24.7%
+38%
FAIR VALUE
GPTHEALTH
Small
GPT Healthcare Limited
Healthcare Services
match 137
70
29.5
28.5%
+41%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Laxmi Dental Limited operates in Dental Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
70Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: cash conversion is weak at 52/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
29 docs text-extracted · 12 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
63rd percentile
overall median 67 · Pharma: 50th pctile, median 70 · Small: 65th pctile, median 66
Evidence depth
Financial-only
29 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
52
watch · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
58
watch · capital discipline
Results
72
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸Debt/equity is 0.05.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸Operating cash flow is negative at ₹-5 Cr.
- ▸ROCE trend is -2.4%.
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Laxmi Dental Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep - Intimation of Schedule of Analyst/ Institutional Investor meetings under the SEBI (LODR), Regulations 2015 to be held on 28th September, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 23 Sep - Intimation of Schedule of Analyst/ Institutional Investor meetings under the SEBI (LODR), Regulations 2015 to be held on 29th September, 2026.
Source: Bse
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 4 Sep - Laxmi Dental schedules analyst/institutional investor group meeting on 9 September 2026, 10:00 AM onwards.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper advertisement for proposed Variation in the Objects/Terms of Utilization of the Initial Public Offering ("IPO") Proceeds and Modification of the Time Limit for Utilization …
Source: Bse
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
AnnouncementAug 2026
Aug 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Aug - Extract of newspaper advertisements published on August 13, 2026, in the Financial Express (English Newspaper) and Mumbai Lakshdeep (Marathi Newspaper), with respect to Unaudited Standalone …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 30 Jun - Pursuant to the Regulation 30 read with Para A Part A of Schedule III of SEBI (LODR), Regulations 2015, as amended from time to time, …
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 11 Aug - Laxmi Dental reported Q1 FY27 revenue of ₹747 million, PAT of ₹103.2 million, up 13.9% YoY.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Jun - Pursuant to the Regulation 30 read with Para A Part A Schedule III of SEBI (LODR), Regulations 2015, as amended from time to time, it …
Source: Bse
Annual report
Annual Report 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.